Table 2.
Efficacy of combined chemotherapy trials in BCBM.
| Authors | Study | Patients | Treatment | ORR (%) | PFS | OS |
|---|---|---|---|---|---|---|
| Franciosi et al. (88) | Prospective | 56 BCBM | Cisplatin + etoposide | 38% | / | 7.1 months |
| Christodoulou et al. (89) | Prospective | 6 BCBM | Cisplatin + temozolomide | / | 2.9 months | 5.5 months |
| Erten et al. (90) | Retrospective | 6 TN BCBM | Cisplatin + gemcitabine | 66.6% | 5.6 months | / |
| Philippe et al. (91) | Prospective | 25 BCBM | Cisplatin + vinorelbine + WBRT | 44% | 3.7 months | 6.7 months |
| Anders et al. (92) | Prospective | 34 TN BCBM | Iniparib + irinotecan | 12% | 2.14 months | 7.8 months |
| Mehta et al. (93) | Prospective | 25 BCBM | Veliparib + WBRT | 41% | / | 7.7 months |
BCBM, breast cancer brain metastases; OS, overall survival; ORR, objective response rate; PFS, progression-free survival; TN, triple negative; WBRT, whole brain radiotherapy.